Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Total Current Liabilities: 2022-2025

Historic Total Current Liabilities for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $58.3 million.

  • NewAmsterdam Pharma Co N.V's Total Current Liabilities rose 41.25% to $58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.3 million, marking a year-over-year increase of 41.25%. This contributed to the annual value of $106.9 million for FY2024, which is 114.28% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's Total Current Liabilities is $58.3 million, which was up 59.60% from $36.5 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Total Current Liabilities registered a high of $106.9 million during Q4 2024, and its lowest value of $38,335 during Q2 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $45.3 million (2024), whereas its average is $48.8 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 118,087.04% in 2024, then crashed by 31.50% in 2025.
  • Quarterly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Total Current Liabilities stood at $36.1 million in 2022, then surged by 38.38% to $49.9 million in 2023, then surged by 114.28% to $106.9 million in 2024, then spiked by 41.25% to $58.3 million in 2025.
  • Its last three reported values are $58.3 million in Q3 2025, $36.5 million for Q2 2025, and $40.9 million during Q1 2025.